G

Grand Pharmaceutical Group Ltd
HKEX:512

Watchlist Manager
Grand Pharmaceutical Group Ltd
HKEX:512
Watchlist
Price: 4.75 HKD 0.21% Market Closed
Market Cap: 16.9B HKD
Have any thoughts about
Grand Pharmaceutical Group Ltd?
Write Note
Grand Pharmaceutical Group Ltd
/
Income Statement
/
Income from Continuing Operations

Grand Pharmaceutical Group Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Grand Pharmaceutical Group Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
G
Grand Pharmaceutical Group Ltd
HKEX:512
Income from Continuing Operations
HK$2.4B
CAGR 3-Years
2%
CAGR 5-Years
21%
CAGR 10-Years
34%
U
United Laboratories International Holdings Ltd
HKEX:3933
Income from Continuing Operations
¥2.9B
CAGR 3-Years
37%
CAGR 5-Years
27%
CAGR 10-Years
18%
Sino Biopharmaceutical Ltd
HKEX:1177
Income from Continuing Operations
¥4.9B
CAGR 3-Years
-26%
CAGR 5-Years
-15%
CAGR 10-Years
12%
C
China Traditional Chinese Medicine Holdings Co Ltd
HKEX:570
Income from Continuing Operations
¥993.3m
CAGR 3-Years
-21%
CAGR 5-Years
-10%
CAGR 10-Years
12%
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Income from Continuing Operations
HK$13.3B
CAGR 3-Years
32%
CAGR 5-Years
10%
CAGR 10-Years
N/A
H
HUTCHMED (China) Ltd
HKEX:13
Income from Continuing Operations
-$42.2m
CAGR 3-Years
37%
CAGR 5-Years
13%
CAGR 10-Years
N/A
No Stocks Found

Grand Pharmaceutical Group Ltd
Glance View

Market Cap
16.9B HKD
Industry
Pharmaceuticals

Grand Pharmaceutical Group Ltd. stands as a significant player in the pharmaceutical industry, strategically positioned in the bustling hub of the Asia-Pacific region. Founded with a vision to harness scientific innovation for healing, the company has diligently expanded its reach and capabilities over the years. Grand Pharma is meticulously structured around three core segments: Medicine and Healthcare, Biopharmaceutical Manufacturing, and Medical Devices. In the Medicine and Healthcare segment, it advances an extensive portfolio of both proprietary and generic drugs. This segment alone accounts for a substantial portion of its revenue, capitalizing on its adeptness in research and development to maintain a robust pipeline of products. By continuously innovating and seeking to meet unmet medical needs, Grand Pharma sustains its competitive edge in the market. Their Biopharmaceutical Manufacturing segment shines brightly as a beacon of future growth, showcasing their commitment to biotechnology. Here, Grand Pharmaceutical leverages cutting-edge biotechnologies to develop therapies targeting a range of complex diseases. This segment is noted for its high-margin potential, driven by the increasing global demand for biologics. Furthermore, their Medical Devices segment complements the pharmaceutical operations by delivering state-of-the-art products in areas such as cardiovascular health and surgical equipment. By maintaining a balanced and diversified portfolio across these business areas, Grand Pharmaceutical effectively mitigates risks and capitalizes on emerging trends in global healthcare markets. Through astute strategic planning and an unwavering commitment to quality and innovation, the company fortifies its position as a leader in the field, continually reinvesting its profits to further enhance its offerings and broaden its impact.

Intrinsic Value
4.74 HKD
Fairly Valued
Intrinsic Value
Price
G
What is Intrinsic Value?

See Also

What is Grand Pharmaceutical Group Ltd's Income from Continuing Operations?
Income from Continuing Operations
2.4B HKD

Based on the financial report for Jun 30, 2024, Grand Pharmaceutical Group Ltd's Income from Continuing Operations amounts to 2.4B HKD.

What is Grand Pharmaceutical Group Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
34%

Over the last year, the Income from Continuing Operations growth was -1%. The average annual Income from Continuing Operations growth rates for Grand Pharmaceutical Group Ltd have been 2% over the past three years , 21% over the past five years , and 34% over the past ten years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.